FDA starts review of Roche’s eye disease drug, setting up 2022 verdictThe FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, Share XFDA starts review of Roche’s eye disease drug, setting up 2022 verdicthttps://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/
Regeneron, AZ team up on drugs for obesity “superpower” geneAstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at Share XRegeneron, AZ team up on drugs for obesity “superpower” genehttps://pharmaphorum.com/news/regeneron-az-team-up-on-drugs-for-obesity-superpower-gene/
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drugThe first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the Share XIntellia, Regeneron ace first trial with ‘in vivo’ CRISPR drughttps://pharmaphorum.com/news/intellia-regeneron-ace-first-trial-with-in-vivo-crispr-drug/
Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
Roche eyes October decision by FDA for wet AMD implantThe FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related Share XRoche eyes October decision by FDA for wet AMD implanthttps://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/
Regeneron drug saves lives in severe COVID-19, but it’s not for allPeople who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron’s Share XRegeneron drug saves lives in severe COVID-19, but it’s not for allhttps://pharmaphorum.com/news/regeneron-drug-saves-lives-in-severe-covid-19-but-its-not-for-all/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Novartis halts three trials of Beovu eye drug on safety concernsProspects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a Share XNovartis halts three trials of Beovu eye drug on safety concernshttps://pharmaphorum.com/news/novartis-halts-three-trials-of-beovu-eye-drug-on-safety-concerns/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
